文献速递瓣膜外科

风湿性二尖瓣修复术后再手术风险的长期纵向分析

Risk of reoperation following rheumatic mitral repair: Long-term longitudinal analysis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-10-09

该回顾性单中心队列研究纳入2000至2022年间因风湿性疾病接受二尖瓣修复的337例患者,以二尖瓣再手术为主要终点,采用Fine-Gray竞争风险模型(死亡为竞争风险)分析。中位随访15.2年,10年和20年累积再手术风险分别为4.5%和12.7%,独立危险因素包括三尖瓣反流速度>3.4 m/s、中重度二尖瓣狭窄、前叶增补和腱索手术。

要点

  • 20年累积再手术风险12.7%,10年为4.5%,长期耐久性受多因素影响
  • 三尖瓣反流速度>3.4 m/s、中重度MS、AMVL增补、腱索手术为独立危险因素
  • 无上述危险因素者20年再手术率仅1.0%,此类患者更适合修复

核心结论

  • 风湿性二尖瓣修复的长期耐久性受肺动脉高压、中重度二尖瓣狭窄、前叶增补及腱索手术等危险因素显著影响;无这些危险因素的患者宜优先选择修复。

研究设计与样本

  • 回顾性单中心队列研究,纳入2000至2022年因风湿性疾病行二尖瓣修复的337例患者,主要终点为二尖瓣再手术,采用Fine-Gray竞争风险模型(死亡为竞争风险)。

主要发现

  • 中位随访15.2年(四分位距7.7-19.4年;总计4629.71患者年),54例死亡,20年生存率78.9%(95%CI 73.6%-84.5%)。
  • 独立危险因素:三尖瓣反流速度>3.4 m/s(HR 3.26;P=.005)、中重度MS(HR 4.39;P<.001)、AMVL增补(HR 5.84;P=.001)、腱索手术(HR 2.99;P=.004)。
  • 0、1、≥2个危险因素患者的20年再手术率分别为1.0%、12.7%、33.6%(P<.001)。

关键数值与推荐

  • 修复技术构成:瓣环成形81.0%、交界处理33.5%、瓣叶切除2.7%、后叶松解14.8%、前叶增补4.2%、Alfieri术2.7%、乳头肌劈开12.8%、腱索手术30.6%。
  • 30天死亡率为0.9%。

临床怎么用

  • 对无三尖瓣反流速度>3.4 m/s、中重度MS等危险因素的风湿性二尖瓣病变患者,优先选择修复;存在前叶增补或腱索手术需求者应充分评估再手术风险并加强随访。

局限性

  • 回顾性单中心设计,结论外推需谨慎;原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate long-term outcomes of rheumatic mitral valve (MV) repair and identify the risk factors of MV reoperation. METHODS: This retrospective, single-center cohort study evaluated 337 patients who underwent MV repair for rheumatic disease between 2000 and 2022. The primary outcome was MV reoperation. Competing risk analyses using Fine-Gray models were performed, with death as the competing risk. RESULTS: MV repair techniques included ring annuloplasty (81.0%), commissure procedures (33.5%), leaflet resection (2.7%), posterior mitral leaflet mobilization (14.8%), anterior mitral leaflet (AMVL) augmentation (4.2%), Alfieri procedure (2.7%), papillary muscle splitting (12.8%), and chordal procedures (30.6%). The 30-day mortality rate was 0.9%. Over a median follow-up of 15.2 years (interquartile range, 7.7-19.4 years; total, 4629.71 patient-years), 54 patients died, with a 20-year survival of 78.9% (95% CI, 73.6%-84.5%). Thirty-two patients required MV reoperation for regurgitation (n = 15), mitral stenosis (MS) (n = 14), and mixed lesions (n = 3). The cumulative risk of reoperation was 4.5% at 10 years and 12.7% at 20 years. Independent risk factors included tricuspid regurgitation velocity >3.4 m/s (hazard ratio [HR], 3.26; P = .005), moderate-to-severe MS (HR, 4.39; P < .001), AMVL augmentation (HR, 5.84; P = .001), and chordal procedures (HR, 2.99; P = .004). The 20-year reoperation rates were 1.0%, 12.7%, and 33.6% in patients with 0, 1, and ≥2 risk factors, respectively (P < .001). CONCLUSIONS: The long-term durability of rheumatic MV repair is significantly affected by such risk factors as pulmonary hypertension, moderate-to-severe MS, AMVL augmentation, and chordal procedures. Repair is preferable in patients without these risk factors.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Shibata M, Kim K, Ono Y, et al. Risk of reoperation following rheumatic mitral repair: Long-term longitudinal analysis. J Thorac Cardiovasc Surg. 2025. PMID: 41067677. doi:10.1016/j.jtcvs.2025.09.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。